Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis.

[1]  Rui Pinto,et al.  Distribution of the high-affinity binding site and intracellular target of botulinum toxin type A in the human bladder. , 2010, European urology.

[2]  D. Dawbarn,et al.  Sequestration of brain derived nerve factor by intravenous delivery of TrkB-Ig2 reduces bladder overactivity and noxious input in animals with chronic cystitis , 2010, Neuroscience.

[3]  I. Nagy,et al.  Functional transient receptor potential vanilloid 1 is expressed in human urothelial cells. , 2009, The Journal of urology.

[4]  M. Chancellor,et al.  Urinary nerve growth factor level is increased in patients with interstitial cystitis/bladder pain syndrome and decreased in responders to treatment , 2009, BJU international.

[5]  M. Chancellor,et al.  Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome , 2009, BJU international.

[6]  M. Fall,et al.  Treatment of bladder pain syndrome/interstitial cystitis 2008: can we make evidence-based decisions? , 2008, European urology.

[7]  L. Lossi,et al.  BDNF as a pain modulator , 2008, Progress in Neurobiology.

[8]  P. Langenberg,et al.  Urinary tract infection and inflammation at onset of interstitial cystitis/painful bladder syndrome. , 2008, Urology.

[9]  G. Lombardi,et al.  Neurogenic detrusor overactivity treated with english botulinum toxin a: 8-year experience of one single centre. , 2008, European urology.

[10]  A. Giannantoni,et al.  Botulinum A toxin intravesical injection in patients with painful bladder syndrome: 1-year followup. , 2008, The Journal of urology.

[11]  G. Karsenty,et al.  Botulinum toxin type a injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux. , 2007, The Journal of urology.

[12]  P. Anand,et al.  Transient receptor potential vanilloid receptor subtype 1 in painful bladder syndrome and its correlation with pain. , 2006, The Journal of urology.

[13]  D. Rapp,et al.  Botulinum toxin type a inhibits calcitonin gene-related peptide release from isolated rat bladder. , 2006, The Journal of urology.

[14]  G. Somogyi,et al.  Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury , 2004, Neurochemistry International.

[15]  M. Chancellor,et al.  Intravesical botulinum toxin a administration produces analgesia against acetic acid induced bladder pain responses in rats. , 2004, The Journal of urology.

[16]  P. Dinis,et al.  Intravesical resiniferatoxin decreases spinal c‐fos expression and increases bladder volume to reflex micturition in rats with chronic inflamed urinary bladders , 2004, BJU international.

[17]  A. Ferrer-Montiel,et al.  Regulated Exocytosis Contributes to Protein Kinase C Potentiation of Vanilloid Receptor Activity* , 2004, Journal of Biological Chemistry.

[18]  M. Fall,et al.  Primary evaluation of patients suspected of having interstitial cystitis (IC). , 2004, European urology.

[19]  J. Roppolo,et al.  Feline interstitial cystitis results in mechanical hypersensitivity and altered ATP release from bladder urothelium. , 2003, American journal of physiology. Renal physiology.

[20]  I. Nagy,et al.  Vanilloid receptor 1 expression in the rat urinary tract , 2002, Neuroscience.

[21]  P. D. De Deyne,et al.  Augmented stretch activated adenosine triphosphate release from bladder uroepithelial cells in patients with interstitial cystitis. , 2001, The Journal of urology.

[22]  Geoffrey Burnstock,et al.  Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X 3-deficient mice , 2000, Nature.

[23]  W. Steers,et al.  Stretch‐activated signaling of nerve growth factor secretion in bladder and vascular smooth muscle cells from hypertensive and hyperactive rats , 2000, Journal of cellular physiology.

[24]  A. Shafik.  Role of the trigone in micturition. , 1998, Journal of endourology.

[25]  G. Sant,et al.  The interstitial cystitis symptom index and problem index. , 1998, Urology.

[26]  P. Dyck,et al.  Intradermal recombinant human nerve growth factor induces pressure allodynia and lowered heat-pain threshold in humans , 1997, Neurology.

[27]  M. Koltzenburg,et al.  Pain and hyperalgesia in acute inflammatory and chronic neuropathic conditions , 1995, The Lancet.

[28]  S L Stanton,et al.  The standardisation of terminology of lower urinary tract function , 1989, World Journal of Urology.

[29]  B. Schurch,et al.  Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. , 2009, European urology.

[30]  M. Fall,et al.  Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. , 2008, European urology.

[31]  Magnus Fall,et al.  The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. , 2003, Urology.